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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYBone marrow-derived mesenchymal stromal cells (BM-MSCs) are capable of differentiating into osteoblasts, chondrocytes, and adipo-
cytes. Skewed differentiation of BM-MSCs contributes to the pathogenesis of osteoporosis. Yet howBM-MSC lineage commitment is regu-
lated remains unclear. We show that ablation of p38a in Prx1+ BM-MSCs produced osteoporotic phenotypes, growth plate defects, and
increased bone marrow fat, secondary to biased BM-MSC differentiation from osteoblast/chondrocyte to adipocyte and increased osteo-
clastogenesis and bone resorption. p38a regulates BM-MSC osteogenic commitment through TAK1-NF-kB signaling and osteoclastogen-
esis through osteoprotegerin (OPG) production by BM-MSCs. Estrogen activates p38a to maintain OPG expression in BM-MSCs to
preserve the bone. Ablation of p38a in BM-MSCs positive for Dermo1, a later BM-MSC marker, only affected osteogenic differentiation.
Thus, p38a mitogen-activated protein kinase (MAPK) in Prx1+ BM-MSCs acts to preserve the bone by promoting osteogenic lineage
commitment and sustaining OPG production. This study thus unravels previously unidentified roles for p38a MAPK in skeletal
development and bone remodeling.INTRODUCTION
Bone marrow-derived mesenchymal stromal cell (BM-
MSC)-derived osteoblasts and chondrocytes are respon-
sible for bone and cartilage modeling/remodeling, respec-
tively (Harada and Rodan, 2003; Wu et al., 2009).
Osteoblasts are defined by lineage-specific transcription
factors RUNX2 and OSTERIX, whereas chondrocytes are
defined by SOX9 (Karsenty, 2008; Long, 2012). In addi-
tion, BM-MSCs are capable of differentiating into adipo-
cytes, which are defined by C/EBPa and PPARg. Under
certain conditions, e.g., aging, the lineage differentiation
potentials of BM-MSCs are altered. Aged BM-MSCs tend
to differentiate into adipocytes at the cost of osteoblasts,
which contributes to the pathogenesis of senile osteopo-
rosis and yellowing of the bone marrow (Baldridge et al.,
2010; Rachner et al., 2011). Reversal of the biased differ-
entiation of aged BM-MSCs is a strategy employed for
the prevention/treatment of osteoporosis (Berendsen
and Olsen, 2014; Kassem and Marie, 2011; Lecka-Czernik566 Stem Cell Reports j Vol. 6 j 566–578 j April 12, 2016 j ª2016 The Authoand Stechschulte, 2014; Zaidi et al., 2012). However, how
BM-MSC lineage commitment is regulated remains less
well understood.
Osteoblast-mediated bone formation is balanced by
osteoclast-mediated bone resorption. Osteoclasts are
derived from hematopoietic stem cell-derived monocytes,
which are defined by transcription factors including PU.1,
NF-kB, and NFATc1 (Edwards and Mundy, 2011). Under
normal conditions, bone formation and resorption are co-
ordinated via complex coupling mechanisms. Some of the
osteogenic regulators, e.g., transforming growth factor b1
(TGFb1), bone morphogenetic proteins (BMPs), and insu-
lin growth factor-1 (IGF-1), are synthesized by osteoclasts
or released from bone matrix during resorption (Crane
and Cao, 2014; Engin and Lee, 2010; Guihard et al.,
2012; Henriksen et al., 2014; Pederson et al., 2008; Take-
shita et al., 2013), whereas the master regulators of osteo-
clast differentiation, macrophage colony stimulating fac-
tor (M-CSF), receptor activator of nuclear factor-kappaB
ligand (RANKL), and osteoprotegerin (OPG), are believedrs
to be produced by osteoblasts, especially osteocytes (Ed-
wards and Mundy, 2011; Karsenty, 2008; Kearns et al.,
2008; Lacey et al., 2012; Lian et al., 2011). Disruption
of bone formation-resorption coupling underlies the etiol-
ogy of osteoporosis (Hofbauer et al., 1999; Michael et al.,
2005).
p38 mitogen-activated protein kinases (MAPKs) are
activated by stress, cytokines, and growth factors, some
of which are involved in bone development and remod-
eling, e.g., TGFb1 and BMPs (Cuadrado and Nebreda,
2010; Han and Sun, 2007; Sorrentino et al., 2008; Yama-
shita et al., 2008). p38 MAPKs phosphorylate a number
of transcription factors such as C/EBPa, MEF2, RUNX2,
SOX9, and p53 to regulate the expression of many target
genes and subsequently cell proliferation, differentiation,
and apoptosis (Greenblatt et al., 2013; Thouverey and
Caverzasio, 2015a). Ablation of p38b or p38a in osteopro-
genitors or osteoblasts revealed that p38 MAPKs play
positive roles in osteoblast maturation, via phosphory-
lating RUNX2/OSX, without affecting osteoclastogenesis
or bone resorption via the coupling mechanisms (Green-
blatt et al., 2010, 2013; Rodriguez-Carballo et al., 2014;
Thouverey and Caverzasio, 2012). Ablation of p38a or
constitutive activation of p38 MAPKs in differentiated
chondrocytes inhibits their differentiation (Hutchison,
2013; Oh et al., 2000; Stanton et al., 2004; Zhang et al.,
2006). Yet it is still unknown whether p38a plays a role
in the stem cells for osteoblasts and chondrocytes,
including their self-renewal and cell fate determination.
Unlike the differentiated cells, the multipotent BM-
MSCs in general do not express lineage-specific tran-
scription factors such as RUNX2 or SOX9, the phosphor-
ylation targets of p38 MAPKs (Greenblatt et al., 2013;
Thouverey and Caverzasio, 2015a). Thus, p38 MAPK
may employ other mechanisms to decide the fates of
BM-MSCs.
Here we ablated p38a, the essential p38 isoform, in BM-
MSCs using Prx1-Cre and Dermo1-Cre mouse lines, respec-
tively, and found that while both Prx1-Cre; p38af/f mice
and Dermo1-Cre; p38af/f mice developed osteoporosis,
Prx1-Cre; p38af/f mice also showed alterations in growth
plate and bone marrow fat. Further studies revealed that
p38a plays a role in self-renewal and lineage determination
of Prx1+ BM-MSCs. Moreover, Prx1-Cre; p38af/f mice, but
not Dermo1-Cre; p38af/f mice, showed increased osteoclas-
togenesis and bone resorption. p38a was found to control
OPG production in Prx1+ BM-MSCs under normal condi-
tions or in response to estrogen. Prx1-Cre; p38af/f mice
were resistant to ovariectomy-induced bone loss. This
study thus reveals that p38a expressed in Prx1+ cells regu-
lates BM-MSC cell fate decision in a cell-autonomous
manner and osteoclastogenesis via controlling production
of OPG.StemRESULTS
Ablation of p38a in Prx1+ BM-MSCs Leads to
Osteoporosis and Cartilage Anomaly
To study the functions of p38a in BM-MSCs, we ablated
p38a with a Prx1-Cre mouse line, which has been used to
delete genes of interest in BM-MSCs (Greenbaum et al.,
2013; Logan et al., 2002). Although inconsistent results
have been reported regarding the in vivo multipotency of
Prx1+ BM-MSCs, our lineage-tracing experiments using
Prx1-Cre; Rosa-tdTomato and Rosa-LacZ mice confirmed
that Prx1 could label osteoblasts, chondrocytes, and bone
marrow adipocytes in vivo (Figure S1A). Immuno-staining
of Prx1-Cre; p38af/fmouse tissues revealed a great reduction
of active p38 MAPKs in osteoblasts and chondrocyte of the
bones, but not in skeletal muscle or heart (Figure S1B). The
mutant mice were born at the expected Mendelian fre-
quency with normal body weight, yet older mice showed
a modest shortening of the hind limbs (Figures S1C and
S1D). Histological analysis revealed that p38a deletion in
Prx1+ BM-MSCs resulted in a decrease in trabecular bone
volume and mineralization (Figure 1A). Histomorphome-
try analysis and micro-computed tomography (CT) anal-
ysis also revealed a decrease in trabecular volume and num-
ber, and an increase in trabecular separation (Table 1 and
Figure 1B). The growth plates were thinner in Prx1-Cre;
p38af/f mice than in control mice (Figures 1A and 1C),
with a decrease in the number of hypertrophic chondro-
cytes (Figure 1C). This may contribute to the short limb
phenotype of the mutant mice. In addition, the mutant
mice showed an increase in bone marrow fat (Figures 1D
and 1E). These results show that ablation of p38a in
Prx1+ BM-MSC and its progenies affects bone mass, carti-
lage and growth plate, and bone marrow fat, validating
the multipotency of Prx1+ BM-MSCs.Ablation of p38a in Dermo1+ BM-MSCs Leads to
Osteoporosis but Not Cartilage Anomaly
In addition to Prx1, Dermo1 has been implicated as a BM-
MSC (or mesenchymal progenitor) marker downstream of
Prx1, and the Dermo1-Cremouse has been used to generate
BM-MSC-specific gene knockout mouse lines as well (Qin
et al., 2015; Tran et al., 2010). Previous studies showed
that bone marrow contains similar numbers of Prx1+ cells
and Dermo1+ cells (Greenbaum et al., 2013; Logan et al.,
2002; Yu et al., 2003). We then ablated p38a using a
Dermo1-Cre knockin mouse line (Logan et al., 2002). Sur-
prisingly, Dermo1-Cre; p38af/f mice did not show a signifi-
cant defect in growth plate or bone marrow fat (Figure S1E
and data not shown), although they showed an osteopo-
rotic phenotype (Table S1). These results suggest that
Dermo1+ BM-MSCs may have limited chondrogenesisCell Reports j Vol. 6 j 566–578 j April 12, 2016 j ª2016 The Authors 567
Figure 1. Deletion of p38a in Prx1+ BM-MSCs Led to Osteopo-
rosis and Growth Plate Defects
(A) Representative images of H&E and Von Kossa staining of the
femur bones of 10-week-old Prx1-Cre; p38af/f and control mice to
show trabecular bones (upper panel, scale bar, 200 mm), bone
mineralization (middle panel, scale bar, 200 mm), and growth plate
(lower panel, scale bar, 50 mm).
(B) Micro-CT results confirmed that Prx1-Cre; p38af/f mice showed
a decrease in bone mass. Bottom panel: quantitation data.
Data represent means ± SEM of eight independent experiments,
**p < 0.01.
(C) The growth plates at a higher magnification. Arrows indicate
hypertrophic chondrocytes. Scale bar, 50 mm.
(D) The Prx1-Cre; p38af/f mice showed an increase in bone marrow
fat. p38a deficiency led to an increase in bone marrow adipocytes
in 8-month-old mice. Arrows indicate the adipocytes in H&E
staining. Scale bar, 50 mm.
(E) The bone marrow smear assay also revealed an increase in bone
marrow fat cells in the mutant mice. Right panel: quantitation data.
Scale bar, 20 mm. Data represent means ± SEM of three independent
experiments. *p < 0.05.
See also Figure S1.
568 Stem Cell Reports j Vol. 6 j 566–578 j April 12, 2016 j ª2016 The Authopotential, thus representing a less primitive BM-MSC pop-
ulation than Prx1+ BM-MSCs.
p38a Controls Proliferation and Multi-Lineage
Differentiation of Prx1+ BM-MSCs
We found that bone formation rates, bone mineralization
rates, and the numbers of osteoblasts were all decreased
in Prx1-Cre; p38af/f mice (Table 1). However, p38a defi-
ciency led to an increase in the number of bone marrow
alkaline phosphatase (ALP)-positive colony-forming units
(Figure 2A), an indication of the number of BM-MSCs.
This was likely caused by enhanced BM-MSC proliferation,
as ablation of p38a led to an increase in proliferation rate
and KI67-positive cells in BM-MSC cultures (Figures 2B
and 2C, and S2A), which was associated with a decrease
in the levels of p53, p21, and p16 (Figure 2C), negative reg-
ulators of cell proliferation that have been shown to be
regulated by p38 MAPKs (Wagner and Nebreda, 2009).
p38a/ bone sections also showed an increase (1.79 ±
0.39 fold, n = 3) in the number of KI67-positive cells,
including marrow cells (Figure 2D). However, p38a defi-
ciency did not affect the apoptosis rates of BM-MSCs or
on bone sections (Figures S2B and S2C).
We then tested the differentiation potentials of p38a/
BM-MSCs and found that Prx1+ BM-MSCs deficient for
p38a showed decreased osteogenic differentiation, mani-
fested by a decrease in ALP staining, mineralization, and
expression of osteoblast-specific markers such as Runx2,
Osx, Fra-1, Atf4, Col1a, and osteocalcin (Figures 2E and
2F, and S2D). The mutant cells also showed decreased
chondrocyte differentiation (Figure 2E), accompanied by
a decrease in Sox9 expression (Figure 2F). The growth plate
phenotype appears to be more severe than that in mice
with p38a ablated in differentiated chondrocytes (Hutchi-
son, 2013). However, the mutant cells showed enhanced
adipocyte differentiation (Figure 2E), accompanied by an
increase in Pparg and C/ebpa expression (Figure 2F). Taken
together, these results suggest that p38a deficiency alters
the multi-lineage differentiation potentials of Prx1+ BM-
MSCs, consistent with thinning of growth plate (Figures
1A and 1C), and an increase in bone marrow adipocytes
observed in Prx1-Cre; p38af/f mice (Figures 1D and 1E).
p38a Regulates BM-MSC Osteogenic Commitment via
TAK1-NF-kB Signaling
Previous studies have shown that p38 MAPKs can promote
osteoblast differentiation by phosphorylating RUNX2/
OSX. Our study and those of others also showed that p38
MAPKswere required forOsx expression (Huet al., 2003;Or-
tuno et al., 2013; Phimphilai et al., 2006;Wang et al., 2007).
YetRunx2 andOsx are expressed inosteoprogenitors andos-
teoblasts but rarely in multipotent BM-MSCs (Figure 3A).
Instead, we found that p38a/ BM-MSCs showedrs
Table 1. Histomorphometry Parameters of Prx1-Cre; p38af/f and Control Mice, Ovariectomized Prx1-Cre; p38af/f and Control Mice
p38af/f Prx1-Cre; p38af/f p38af/f OVX Prx1-Cre; p38af/f OVX
BV/TV (%) 22.914 ± 5.66 10.336 ± 5.79** 15.552 ± 2.76** 12.017 ± 3.99
Tb.Ar (%) 19.711 ± 4.90 5.827 ± 2.78** 12.241 ± 2.09** 8.238 ± 2.36
Tb.Th (mm) 36.669 ± 2.86 18.766 ± 3.13** 26.768 ± 2.88** 20.713 ± 4.52
Tb.Sp (mm) 193.124 ± 30.73 540.127 ± 211.85* 355.784 ± 41.12** 448.729 ± 28.23
Tb.N (no./mm) 5.950 ± 0.76 2.70 ± 1.51** 3.646 ± 0.33** 2.769 ± 0.41
MAR (mm/d) 1.749 ± 0.168 1.243 ± 0.097** 1.768 ± 0.096 1.240 ± 0.188
BFR (mm/d) 75.880 ± 3.896 56.437 ± 4.58** 71.771 ± 3.88 55.970 ± 6.1
OB.S/BS (%) 17.016 ± 1.096 11.600 ± 1.68** 16.001 ± 1.00 11.933 ± 0.95
Data represent means ± SEM of eight independent experiments, **p < 0.01, *p < 0.05 when the value of mutant or ovariectomized mice was compared with
that of control mice.
See also Table S1.enhanced activation of the TAK1-NF-kB pathway (Fig-
ure 3B), which has been recently shown to inhibit BM-
MSC osteogenic differentiation (Chang et al., 2009; Yao
et al., 2014; Yu et al., 2014). p38 MAPKs have been shown
to phosphorylate TAB1/2 to inhibit TAK1 activation in
several cell types (Cheung et al., 2003; Wagner and
Nebreda, 2009). We found that inhibition of TAK1 with
5Z-7-oxozeaenol or inhibition of NF-kB with BAY11-7082,
reversed the osteogenic differentiation defects of p38a/
BM-MSCs, manifested by the decrease in ALP staining,
mineralization staining, and expression of osteoblast
markers (Figures S3A–S3C), although the effects of the
inhibitors on osteogenic differentiation of wild-type
(WT) BM-MSCs were rather modest. These findings were
confirmed by knockdownofTak1 orNf-kB (p65)with siRNA
in p38a/ BM-MSCs (Figures 3C and 3D). These results
suggest that p38a can regulate osteogenic differentiation
ofPrx1+BM-MSCs via theTAK1-NF-kBpathway. At the later
stages of osteoblastogenesis, p38MAPKmay act on RUNX2
andOSTERIX to further promote osteoblast differentiation.
Ablation of p38a in BM-MSC Promotes
Osteoclastogenesis In Vivo and In Vitro
We noticed that in Prx1-Cre; p38af/f mice, the extent of the
decrease in bone mass (down to 45.4% of the control) ex-
ceeds that of the decrease in bone formation rates (down
to 74.3% of the control) (Table 1), suggesting that bone
resorption may contribute to the osteoporotic phenotype
as well. Indeed, we found that Prx1-Cre; p38af/f mice
showed an increase in osteoclast surface, the number of os-
teoclasts (Figures 4A and 4B), and the levels of urine deox-
ypyridinoline (DPD), an in vivo bone resorption marker
(Figure 4C), suggesting that ablation of p38a in Prx1+
BM-MSCs promoted osteoclastogenesis and bone resorp-
tion in a non-cell-autonomous way. This activity of p38aStemappears to be unique to Prx1+BM-MSCs as previous studies
have reported that ablation of p38a or p38b in osteoproge-
nitors or osteoblasts did not affect osteoclastogenesis or
bone resorption (Greenblatt et al., 2010; Rodriguez-Car-
ballo et al., 2014; Thouverey and Caverzasio, 2012). We
found that ablation of p38a inDermo1+ cells did not signif-
icantly alter the number of osteoclasts or bone resorption
rate (Figure S1F). These results, together with our observa-
tion that Dermo1+ cells have minimal chondrogenic activ-
ity, suggest that p38a plays an important role in BM-MSC-
osteoclastogenesis coupling, but not in osteoprogenitor/
osteoblast communication to osteoclastogenesis.
We also found that in co-culture experiments, BM-MSCs
were able to support osteoclastogenesis and more impor-
tantly, p38a/ BM-MSCs showed a heightened ability in
promoting osteoclastogenesis (Figure 4D). Similarly, the
p38a/ BM-MSC culture medium was more capable of
promoting osteoclast differentiation than the WT BM-
MSC culture medium (Figure 4E). These results suggest
that p38a deficiency might affect the synthesis of RANKL,
M-CSF, OPG, or othermolecules that are involved in regula-
tionof osteoclastogenesis. Thefinding that ablationof p38a
in BM-MSCs but not in osteoblasts affects osteoclastogene-
sis may be explained by differential expression of RANKL,
OPG, or M-CSF in BM-MSCs and osteoblasts. Yet qPCR as-
says revealed that these two cell types expressed similar
levels ofRankl,Opg, andM-csfat themRNAlevels (Figure S4).
p38a Regulates the Expression of Opg via CREB in
Prx1+ BM-MSCs
We found that p38a deficiency led to a 4-fold decrease in
the mRNA levels of Opg (Figure 5A), and a modest increase
inmRNA levels ofM-csf and Rankl (Figure 5A). A decrease in
OpgmRNA levels and a modest increase in Rankl andM-csf
levels were also observed in the bone extracts of Prx1-Cre;Cell Reports j Vol. 6 j 566–578 j April 12, 2016 j ª2016 The Authors 569
Figure 2. p38a Ablation Enhanced Prolif-
eration of Prx1+ BM-MSCs and Resulted
in Skewed BM-MSC Tri-lineage Differen-
tiation
(A) Prx1-Cre; p38af/f mice showed an in-
crease in the number of ALP-positive col-
ony-forming units. A total of 53 106 cells/
well was plated onto six-well plates, which
were stained for ALP after 7 days in culture.
Bottom panel: quantitation data. Data
represent means ± SEM of three indepen-
dent experiments, **p < 0.01.
(B) p38a/ BM-MSC showed increased
proliferation. WT and Prx1-Cre; p38af/f BM-
MSCs were cultured in BM-MSC culture me-
dium and cells were counted at different
time. Data represent means ± SEM of three
independent experiments, **p < 0.01.
(C) Ablation of p38a in BM-MSC showed a
decrease in p38a, p16, p53, and p21 protein
levels compared with control cells. The BM-
MSCs were isolated from WT and Prx1-Cre;
p38af/f mice, cultured in BM-MSC culture
medium to log phase, and were then
collected. The protein levels of these genes
were analyzed by western blot.
(D) p38a/ bone sections also showed an
increase in the number of KI67-positive
cells. Scale bar, 100 mm.
(E) p38a/ BM-MSC showed an alteration
in differentiating into the three lineages.
WT and p38a/ BM-MSCs were cultured in
differentiation medium for osteoblasts,
chondrocytes, or adipocytes for different
periods of time and then stained for ALP,
mineralization, Alcian blue (scale bar,
100 mm), or oil red O (scale bar, 20 mm).
Right panel: quantitation data to show the numbers of chondrocytes and adipocytes per well. Data represent means ± SEM of three
independent experiments, **p < 0.01.
(F) p38a/ BM-MSCs showed an alteration in the expression of lineage-specific transcription factors and functional molecules. The cells
were cultured as described in Figure 3E, from which total RNA was isolated. qPCR was used to determine the mRNA levels of these genes.
Data represent means ± SEM of three independent experiments, **p < 0.01.
See also Figure S2.p38af/fmice (Figure 5B). In co-culture experiments, supple-
menting the p38a/ BM-MSC-monocytes co-culture with
OPG could inhibit osteoclast differentiation (Figure 5C).
These results suggest that p38a/ BM-MSC may promote
osteoclastogenesis by down-regulating OPG.
It is likely that p38a controls Opg transcription via its
downstream transcription factors. Screening of these tran-
scription factors with siRNA revealed that Creb may be
involved (data not shown). We found that p38a deficiency
led to a decrease in CREB phosphorylation on Ser133 and
moreover, knockdown of Creb with siRNA significantly
decreased themRNA levels ofOpg in normal BM-MSCs (Fig-570 Stem Cell Reports j Vol. 6 j 566–578 j April 12, 2016 j ª2016 The Authoures 5D and 5E), suggesting that CREB is required for
expression of OPG in BM-MSCs. Chromatin-immunopre-
cipitation (ChIP) assays revealed that two CREB binding
sites exist in the promoter of Opg gene (Figure 5F). Taken
together, our results showed that Opg transcription in
BM-MSCs is regulated by the p38a-CREB axis and that
Opg is a target gene of CREB.
Prx1-Cre; p38af/f Mice Are Resistant to Estrogen
Deficiency-Induced Bone Loss
The above studies revealed that the p38a-CREB-OPG axis
in BM-MSCs regulates osteoclastogenesis. One of thers
Figure 3. p38a Regulated BM-MSC Osteo-
genic Differentiation via TAK1-NF-kB
Signaling
(A) p38a/ and WT BM-MSCs showed
minimal expression of Runx2 and Osx. Data
represent means ± SEM of three indepen-
dent experiments, **p < 0.01.
(B) p38a/ BM-MSCs showed enhanced
TAK1-NF-kB signaling. BM-MSCs were iso-
lated from p38af/f mice and cultured in BM-
MSC medium, infected with Cre-expressing
retrovirus or empty retrovirus, selected
against puromycin, and then collected. The
activation and protein levels of TAK1, NF-
kB, and p38a were determined by western
blot analysis.
(C) Knockdown of Tak1 or Nf-kb p65 with
siRNA rescued the osteogenic differentia-
tion defect of p38a/ BM-MSCs. WT and
p38a/ BM-MSCs were transfected with
control, Tak1, or Nf-kb siRNA for 2 days and
then cultured in osteoblast differentiation
medium for 4 more days. The cells were
stained for ALP (right panel). Left panel:
western blot results of knockdown of TAK1
or NF-kB.
(D) qPCR results showed that knock-
down of Tak1 or Nf-kb p65 with siRNA
rescued the osteogenic differentiation
defect of p38a/ BM-MSCs. Data repre-
sent means ± SEM of three independent
experiments, **p < 0.01.
See also Figure S3.pathological conditions that involves osteoblast-osteoclast
interaction is estrogen deficiency-induced osteoporosis,
which affects more than 50% of women over 50 years of
age (Manolagas et al., 2013; Rachner et al., 2011).We found
that estradiol activated p38 MAPKs in a time- and dose-
dependent manner in BM-MSCs (Figures 6A and 6B), and
ovariectomy led to a decrease in p38 MAPKs activation
on bone sections, in particular the osteoblast-like cells
aligning the trabecular bone surface (Figure 6C), suggesting
that p38aMAPK is a nongenomic signaling molecule of es-
trogen. Moreover, we found that p38a deficiency down-
regulated themRNA and protein levels of estrogen receptor
a (ERa) but not ERb in BM-MSCs and osteoblasts (Figures
S5A and S5B), suggesting that p38a is required for optimal
expression of ERa in these cells.
Furthermore, estradiol promoted Opg expression in WT
BM-MSCs but not in p38a/ BM-MSCs, suggesting a
necessary role for p38a in estrogen-inducedOpg expression
(Figure 6D). Moreover, p38a/ osteoblasts were notStemresponsive to estradiol-induced Opg expression (Fig-
ure S5C). In addition to inhibiting p38 MAPK activation,
ovariectomy also down-regulated Opg expression in the
bone of WT mice. The basal levels of Opg in the bones of
Prx1-Cre; p38af/fmice were low, which could not be further
down-regulated by ovariectomy (Figure 6E). These results
suggest that estrogen may induce OPG expression via
p38a in BM-MSCs and osteoblasts to suppress osteoclasto-
genesis. If this p38a-controlled OPG production plays a
role in the bone-sparing effects of estrogen, ovariectomy
would not further affect osteoclastogenesis or bone resorp-
tion in Prx1-Cre; p38f/f mice due to low levels of OPG.
We ovariectomized Prx1-Cre; p38af/f and control mice and
waited for 4 weeks before analyzing the bone parameters,
and found that ovariectomy led to a decrease in bone
mass in normalmice, which is accompanied by an increase
in the number of osteoclasts and bone resorption rate
(Table 1; Figures 6F and 6G), yet ovariectomy did not
further reduce the bone mass in Prx1+ BM-MSC-specificCell Reports j Vol. 6 j 566–578 j April 12, 2016 j ª2016 The Authors 571
Figure 4. Ablation of p38a in Prx1+ BM-
MSCs Promoted Osteoclastogenesis and
Bone Resorption
(A) Prx1-Cre; p38af/f mice showed an in-
crease in the osteoclast surface per bone
surface. Data represent means ± SEM of
eight independent experiments, *p < 0.05.
(B) Prx1-Cre; p38af/f mice showed an in-
crease in the number of osteoclasts per bone
surface. Data represent means ± SEM of
eight independent experiments, *p < 0.05.
(C) Prx1-Cre; p38af/f mice showed an in-
crease in the levels of urine DPD. Urine
levels of DPD were determined with an ELISA
kit and were normalized to urine levels of
creatine. Data represent means ± SEM of
eight independent experiments, *p < 0.05.
(D) Co-culture experiments showed that
p38a/ BM-MSCs had increased potential
to support osteoclastogenesis. WT and
p38a/ BM-MSCs were plated in BM-MSC
culturemediumand, after 24hr, bonemarrow
monocytes isolated from normal mice were
added onto the BM-MSC cultures, which were
cultured in the absence of RANKL or M-CSF.
After 7 days, the plateswere stained for TRAP.
Right panel: quantitation data to show the
number of osteoclasts per view. Scale bar,
100 mm. Data representmeans± SEM of three
independent experiments, *p < 0.05.
(E) p38a/ BM-MSC culture medium also showed increased potential to support osteoclastogenesis. Right panel: quantitation data to
show the number of osteoclasts per view. Scale bar, 100 mm. Data represent means ± SEM of three independent experiments, *p < 0.05.
See also Figure S4.p38a knockoutmice, nor did it further increase the number
of osteoclasts or bone resorption rate (Table 1; Figures 6F
and 6G). Note that ovariectomy showed no significant
effect on bone formation in WT or Prx1-Cre; p38af/f mice,
and estradiol did not show any significant effects on the
differentiation of BM-MSCs and osteoblasts (Table 1 and
data not shown). These results suggest that estrogen defi-
ciency regulates in vivo osteoclastogenesis and bone
resorption mainly through p38a-mediated expression of
OPG in Prx1+ BM-MSCs.DISCUSSION
As stem cells of the skeleton, BM-MSC’s lineage commit-
ment, a crucial step thought to determine the yield of func-
tional osteoblasts, needs to be tightly regulated. Yet how
BM-MSC lineage commitment is regulated remains poorly
understood. This study revealed that p38aMAPK regulates
tri-lineage commitment and proliferation of BM-MSCs.
p38a MAPK deficiency compromises osteogenic/chondro-572 Stem Cell Reports j Vol. 6 j 566–578 j April 12, 2016 j ª2016 The Authogenic differentiation but favors adipogenic differentiation,
and results in a decrease in bone mass, a defect in growth
plate, and an increase in bone marrow fat. Previous studies
have implicated that YAP, C-MAF, and VEGF differentially
regulate osteoblast and adipogenic differentiation of BM-
MSCs (Hong et al., 2005; Liu et al., 2012; Nishikawa et al.,
2010). It will be interesting to test whether there exist links
between p38 MAPKs and YAP, C-MAF, or VEGF in the
context of BM-MSC lineage commitment. These proteins
may present a class of targets for drug development for oste-
oporosis prevention/treatment.
Our data suggest that p38a may promote BM-MSC oste-
ogenic commitment by suppressing the NF-kB pathway.
Previous studies suggest that p38a and p38b promote oste-
oblast differentiation via modifying RUNX2 and OSX
(Greenblatt et al., 2013). But lineage-specific transcription
factors such as RUNX2 and OSX are in general not ex-
pressed in multipotent BM-MSCs, and thus p38 MAPKs-
mediated phosphorylation of these proteins may not be a
major factor in determining the cell fates of BM-MSCs
(Chang et al., 2009; Yu et al., 2014). Thus, p38a mayrs
Figure 5. p38a Positively Regulated OPG
Expression via CREB
(A) p38a/ BM-MSCs showed a decreased
expression of OPG and a modest increase in
RANKL and M-CSF compared with WT BM-
MSCs. Total RNA was isolated from WT and
p38a/ BM-MSCs and was used to deter-
mine the mRNA levels of Opg, Rankl, and
M-csf. Data represent means ± SEM of three
independent experiments, **p < 0.01.
(B) Prx1-Cre; p38af/f mouse bones also
showed a decrease in Opg mRNA levels and a
modest increase in Rankl and M-csf. The
femur bones were frozen and total RNA was
isolated. Data represent means ± SEM of six
independent experiments, **p < 0.01.
(C) Addition of OPG to the p38a/ BM-
MSCs co-cultured with normal monocytes
impeded the enhanced osteoclast differen-
tiation. The experiments were carried out as
described in Figure 4D, except that OPG
(20 ng/ml) was added to the cultures. Scale
bar, 100 mm.
(D) p38a/ BM-MSCs showed a decrease
in CREB phosphorylation. WT and p38a/
BM-MSCs were collected and lysed. The levels
of CREB and p-CREB were determined by
western blot.
(E) Knockdown of Creb led to a down-regu-
lation of Opg in normal BM-MSCs. BM-MSCs
were transfected with control or siRNA
against Creb. qPCR was carried out to
determine the mRNA levels of Opg. Right
panel: western blot showing the knockdown of CREB. Data represent means ± SEM of three independent experiments, **p < 0.01.
(F) ChIP experiments showed that Opg promoter has two CREB binding sites at501 to601 and1201 to1301. Right panel: a diagram
showing the binding sites of CREB in the promoter of Opg gene. Data represent means ± SEM of three independent experiments, **p < 0.01.regulate BM-MSC osteogenic commitment and osteoblast
maturation with different mechanisms (Figure 6H). More-
over, p38amay promote BM-MSCosteogenic commitment
by suppressing the competing adipogenic or chondrogenic
commitment through down-regulating PPARg, C/EBPa,
and SOX9, transcription factors essential for commitment
of these two lineages (Kozhemyakina et al., 2015).
p38a deficiency led to a decrease in the number of osteo-
blasts on bone sections, which can be caused by defective
BM-MSC osteogenic differentiation. Surprisingly, the num-
ber of BM-MSCs and the BM-MSC proliferation rate were
increased in the absence of p38a. This seeming discrepancy
may be explained by the fact thatmouse bonemarrowmay
contain MSCs that outnumber the bone multicellular
units, where new bone formation is occurring. Although
p38a ablation leads to overproliferation of BM-MSCs, a
large portion of these cells may not be actively involved
in bone formation. Thus, the number of BM-MSCs is not
directly translated into the number of osteoblasts.StemWe found that the function of BM-MSC-expressed p38a
is not limited to osteoblastogenesis and bone formation.
We show that p38a-controlled, CREB-mediated OPG pro-
duction by BM-MSCs is critical for coupling bone forma-
tion and resorption. This is in contrast to the findings
that ablation of p38a or p38b in osteoprogenitors/osteo-
blasts or Dermo1+ cells failed to affect osteoclastogenesis
or bone resorption (Greenblatt et al., 2010; Thouverey
and Caverzasio, 2012). Thus, only p38a expressed in BM-
MSCs but not in osteoblasts is involved in communicating
with monocytes/osteoclasts under physiological condi-
tions. One explanation is that in a bone remodeling unit,
the newly recruited BM-MSCsmay secrete OPG to immedi-
ately inhibit further osteoclastogenesis, whereas osteo-
blast-secreted OPG molecules are embedded in the newly
formed bone matrix and are not accessible to monocytes/
osteoclasts. Alternatively, osteoblasts may have pathways
redundant for p38a-OPG to communicate to osteoclasto-
genesis under physiological conditions.Cell Reports j Vol. 6 j 566–578 j April 12, 2016 j ª2016 The Authors 573
Figure 6. The p38-OPG Axis in BM-MSCs
Participated in Estrogen Deficiency-
Induced Osteoporosis
(A) Estradiol activated p38 MAPKs in a time-
dependent manner in BM-MSCs. Normal BM-
MSCs were stimulated with 10 nM of estra-
diol for different periods of time and the
activation of p38 MAPKs was determined by
western blot.
(B) Estradiol activated p38 MAPKs in a dose-
dependent manner in BM-MSCs.
(C) Ovariectomy diminished p38 MAPKs
activation on bone sections. WT mice
were ovariectomized or sham-operated.
The femur bones were decalcified, and
immuno-stained for p-p38 MAPKs. The
bone from Prx1-Cre; p38af/f mice was
used as a negative control. The red
dashed lines mark the bone surfaces.
Scale bar, 100 mm.
(D) Estradiol induced Opg expression in a
p38a-dependent manner. WT and p38a/
BM-MSCs were treated with estradiol for
24 hr and the mRNA levels of Opg were
determined with qPCR. Data represent
means ± SEM of three independent experi-
ments, **p < 0.01.
(E) Ovariectomy down-regulated Opg
expression in the bone in a p38a-dependent
manner. Total RNA was isolated from femur
bones and Opg levels were determined with
qPCR. Data represent means ± SEM of three
independent experiments, **p < 0.01.
(F) Ovariectomy did not further increase the number of osteoclasts in Prx1-Cre; p38af/f mice. Data represent means ± SEM of eight
independent experiments, **p < 0.01.
(G) Ovariectomy did not further increase the level of urine DPD levels in Prx1-Cre; p38af/f mice. Data represent means ± SEM of eight
independent experiments, **p < 0.01.
(H) A diagram showing how p38a is involved in osteoblastogenesis, osteoclastogenesis, and their coordination during bone remodeling.
See also Figure S5.The p38-CREB-OPG pathway in BM-MSCs is also under
the control of estrogen. We show that p38a MAPK can be
activated by estrogen and that p38a is also required for
optimal expression of ERa. Activated p38amediates estro-
gen-induced OPG expression in BM-MSCs, which helps to
maintain the bone mass under physiological conditions.
Estrogen deficiency leads to a decrease in p38aMAPK acti-
vation and OPG synthesis, leading to an increase in osteo-
clastogenesis and bone resorption (Figure 6H). As such,
Prx1+ BM-MSC-specific deletion of p38a renders the mice
resistant to estrogen deficiency-induced bone loss. Interest-
ingly, a recent study reported that mice with p38a ablated
in osteoblasts are also resistant to ovariectomy-induced
bone loss, likely via RANKL and interleukin 6 (IL6) (Thou-
verey and Caverzasio, 2015b). These results confirm the
important role for p38a in BM-MSCs and osteoblasts in574 Stem Cell Reports j Vol. 6 j 566–578 j April 12, 2016 j ª2016 The Authocommunicating to osteoclastogenesis under estrogen-
deficient conditions, although these two cells may use
differentmechanisms.While recent studies suggest that es-
trogen may promote osteoclast apoptosis and thus inhibit
bone resorption to preserve the bone (Krum et al., 2008;
Nakamura et al., 2007), these findings suggest that the
contribution of BM-MSC/osteoblast-osteoclast coupling
to the pathogenesis of postmenopausal osteoporosis may
be greater than previously thought.
Previous studies have shown that BM-MSCs can be
labeled by markers including Prx1, Dermo1, leptin receptor,
and Nestin (Mendelson and Frenette, 2014; Morrison and
Scadden, 2014). Our lineage-tracing experiments confirm
that Prx1+ BM-MSCs can differentiate into osteoblasts,
chondrocytes, and adipocytes in vivo. Moreover, deletion
of p38a MAPK in Prx1+ cells affects bone mass, growthrs
plates, and bone marrow fat, as well as osteoclastogenesis
and bone resorption. However, deletion of p38a in
Dermo1+ cells, like deletion of p38a in osteoblasts, only af-
fects BM-MSC osteogenic differentiation and bone forma-
tion. These results suggest that Prx1 may be a much early
marker than Dermo1 and that Dermo1+ cells may represent
a BM-MSC population with limited chondrogenic activity.
In summary, the present study shows that BM-MSC-ex-
pressed p38a may take two routes to maintain bone mass
and prevent the development of osteoporosis. In particular,
p38a is required for proper BM-MSC osteogenic commit-
ment, via the TAK1-NFkB pathway, to maintain proper
bone formation, and for OPG synthesis by BM-MSCs to
constrain osteoclastogenesis and bone resorption. More-
over, estrogen appears to go through the p38-OPGpathway
to preserve the bone. Cytokines or growth factors that can
activate p38 MAPKs, e.g., TGFb1, BMPs, TNFa, and IL6
(Cuadrado and Nebreda, 2010; Han and Sun, 2007; Sorren-
tino et al., 2008; Yamashita et al., 2008), may regulate bone
remodeling via p38a as well.EXPERIMENTAL PROCEDURES
Mice and Genotyping
The p38af/f mouse line was generated in Dr. Yibin Wang’s labora-
tory at UCLA. The Dermo1-Cre, Prx1-Cre, Rosa-LacZ, and Rosa-
tdTamato mouse lines were purchased from The Jackson Labora-
tories. These mice were housed in a pathogen-free facility at the
Bio-X Institutes at Shanghai Jiao Tong University and the experi-
mental protocol was approved by the Animal Welfare Committee
of the University.Bone Histomorphometry
Two-month-old mice were injected twice with calcein at a dose of
0.2 mg/20 g body weight with an interval of 7 days and were sacri-
ficed 1 day after the second injection. Bone histomorphometry
analysis was carried out following a protocol that has been previ-
ously described (Kua et al., 2012; Ma et al., 2012). Briefly, the
femurs were removed and fixed in 4% paraformaldehyde (PFA)
overnight and then stored in 70% alcohol for future experiments.
The bones were dehydrated in 95% ethanol overnight, 100%
ethanol for 5 hr, 100% ethanol again overnight, and then trans-
ferred into xylene overnight, and vacuumed for 30min. The bones
were then embedded with resin, sliced, and stained with Villa-
nueva-Goldner’s one-step trichrome method. All bone-specific
parameters were measured and expressed in units following the
guidelines established by the American Society for Bone and
Mineral Research histomorphometry nomenclature committee
using OsteoMeasure software (OsteoMetrics).Deoxypyridinoline Measurement
Deoxypyridinoline in the urine was determined to evaluate the
bone resorption rate, following the procedure recommended by
the manufacturer MicroVue (Quidel).StemBone Marrow Smear and Colony-Forming Unit Assay
Bone marrow cells were flushed out onto slides using a-MEM
(Sigma), followed by oil red O and DAPI staining. Adipocytes and
total marrow cells were counted on ten randomly selected fields
of each smear. Adipocyte number is expressed as a percentage of
the total numbers of bone marrow cells. To determine colony-
forming units, bone marrow cells were prepared, with red blood
cells lysed, and plated at 5 3 106 per well in six-well plates. Fresh
complete a-MEM medium was changed every 3 days. Seven days
later, the plates were washed with cold PBS, fixed with 4% PFA
for 30 min, and stained for ALP (Sigma).
Assays for BM-MSC Osteogenic, Chondrogenic, and
Adipogenic Differentiation
Bone marrow MSCs were isolated from control and mutant mice,
whichwere expanded in BM-MSC stem cellmedium to prevent dif-
ferentiation. BM-MSCs at passage 2 were plated and transfected
with siRNA for Tak1 or NF-kB (p65), or control siRNA, induced to
differentiate into osteoblasts in the presence of osteogenic differ-
entiation medium, which contains ascorbic acid and b-glycerol-
phosphate. An Alkaline Phosphatase Kit (Sigma) was used to stain
for ALP enzymatic activity, following the manufacture’s protocol.
To determine mineralization, 21- or 28-day cell cultures were fixed
in 4% PFA for 20 min, and stained with alizarin red. Adipogenesis
of BM-MSC was induced with a StemPro Adipogenesis Differentia-
tion Kit (Gibco), which was detected by oil red O staining. Chon-
drogenesis was induced using a StemProChondrogenesis Differen-
tiation Kit (Gibco) and staining with 1% Alcian blue solution.
Co-culture of BM-MSC and Monocyte
Co-culture experiments were carried out following a protocol that
has been previously described (Kua et al., 2012). Mouse bone
marrow was flushed out with a-MEM medium from the femurs
and tibias. The monocyte fraction was isolated by centrifugation
on a Ficoll plus lymphocyte separationmedium gradient (ICN Bio-
medicals). For co-cultures, primary BM-MSCwere plated at 53 104
per well in 24-well plates for 24 hr. Upon confluency, freshly iso-
lated bone marrow monocytes were then plated (5 3 105) on top
of the BM-MSCs and cultured for 6–10 more days, with the me-
dium being changed every 3 days. The cells were then fixed and
stained for tartrate-resistant acidic phosphatase (TRAP) using the
Acid Phosphatase, Leukocyte TRAP Kit (Sigma), following the
manufacturer’s protocol. TRAP-positivemultinucleated osteoclasts
were counted (R3 nuclei).
Immunohistochemical Staining and TUNEL Assay
Detection of p-p38MAPK was performed on paraffin sections of fe-
mur or tibia by immunohistochemistry staining. Tissue sections
were processed with an antigen retrieval step before they were
incubated with anti-p-p38 antibodies overnight at 4C. These
slides were then washed three times with PBS, incubated with
horseradish peroxidase-labeled anti-rabbit antibody for 30 min at
37C, and developed with diaminobenzidine tetrahydrochloride
and hydrogen peroxide in PBS. Cell proliferation and apoptosis
were determined by KI67 immunofluorescence staining (Abcam,
ab15580) and TUNEL assay (In Situ Cell Death Detection Kit Fluo-
rescein, Roche), respectively.Cell Reports j Vol. 6 j 566–578 j April 12, 2016 j ª2016 The Authors 575
Western Blot Analysis
BM-MSCor osteoclastswere lysedwith TNENbuffer supplemented
with protease inhibitors and phosphatase inhibitors. Protein con-
centration was determined using a Bio-Rad assay. Twenty micro-
grams of protein lysates of each sample was subjected to SDS-
PAGE analysis and transferred onto nitrocellulose membranes.
The proteins were detected with specific antibodies (listed in the
Supplemental Information).
ChIP Assays
ChIP assays were carried out following the protocol from the
SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling, 9002).
Briefly, BM-MSCs or osteoclasts (4 3 107) were treated with 1%
formaldehyde for 10 min at room temperature to crosslink
proteins to DNA. The chromatin was harvested and fragmented
using enzymatic digestion. An aliquot of each sample was set aside
as input control, while the remaining portion was subjected
to immunoprecipitation with anti-CREB antibodies (Upstate,
05767) overnight at 4C, with IgG (Beyotime) as control. Immuno-
precipitated complex was treated with protease and the DNA was
amplified by PCR using primer pairs designed to amplify about
100-bp fragments spanning the 2-kb Opg promoter (BM-MSCs).
Data Analysis
For bone histomorphometry analysis, eightmutant and eight con-
trol mice were used. For ex vivo studies, at least three pairs of mice
were used. In vitro experiments were repeated three times. Results
are presented as means ± SEM. Statistical comparisons were per-
formed using unpaired Student’s two-tailed t test. p < 0.05 was
considered statistically significant (*p < 0.05, **p < 0.01 when
mutantmicewere comparedwith controlmice, siRNA knockdown
cells were compared with control cells, or the inhibitor-treated
group were compared with control group).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, five figures, and one table and can be found with this
article online at http://dx.doi.org/10.1016/j.stemcr.2016.02.001.
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